BioCentury
ARTICLE | Clinical News

Alexion's long-acting C5 inhibitor meets in Phase III switch trial

April 27, 2018 7:51 PM UTC

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported in its 1Q18 earnings release on April 26 that ALXN1210, its long-acting formulation of Soliris eculizumab, met the primary and four key secondary endpoints in the the Phase III ALXN1210-PNH-302 trial to treat paroxysmal nocturnal hemoglobinuria (PHN) in patients who were clinically stable on Soliris for at least six months.

Alexion now plans to submit regulatory applications for ALXN1210 to treat PNH in the U.S. and EU in mid-2018, followed by Japan later this year. The company had previously said it planned to submit regulatory applications next half for ALXN1210...

BCIQ Company Profiles

Alexion Pharmaceuticals Inc.

BCIQ Target Profiles

Complement 5 (C5)